Comparing Effect of Shock Wave Alone Versus Shock Wave With Traditional Physical Therapy for Tennis Players With Chronic Supraspinatus Tendinitis

November 10, 2026 updated by: yasmein mohammed mahmoud, Kafrelsheikh University

Study Goal: To compare the effect of shock wave therapy alone versus shock wave therapy combined with traditional physical therapy for tennis players suffering from chronic supraspinatus tendinitis.

Study Design: A pre-post randomized controlled experimental trial where participants are randomly assigned into two equal groups.

Participants: 70 tennis players of both genders (aged 16 to 65 years) with chronic supraspinatus tendinitis, divided into 35 participants per group.

Intervention & Duration: The treatment period consists of 12 sessions spanning one and a half months.

Evaluation Metrics: Shoulder range of motion (measured via electronic goniometer), shoulder pain (measured via numeric anlage scale), and shoulder function (assessed via shoulder joint functional index).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 65 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Tennis players
  • Diagnosed with chronic supraspinatus tendinitis
  • Aged 16 to 65 years
  • Of both genders
  • Willing to sign a consent form according to the Helsinki Protocol

Exclusion Criteria:

  • A history of previous shoulder surgery or fracture on the affected side.
  • Full-thickness rotator cuff tears confirmed by clinical evaluation or imaging.
  • Receipt of a local corticosteroid injection in the affected shoulder within the past three months.
  • Presence of acute shoulder trauma, dislocation, or severe joint instability.
  • Concomitant shoulder pathologies such as adhesive capsulitis (frozen shoulder) or referred pain from cervical radiculopathy.
  • Bleeding disorders or ongoing anticoagulant therapy that may contraindicate shock wave treatment.
  • Presence of a cardiac pacemaker or metallic implants in the shoulder region.
  • Pregnancy or lactation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Shock Wave Therapy Alone

Participants will receive 12 sessions of extracorporeal shock wave therapy (ESWT) alone, administered at a frequency of two sessions per week for a total duration of one and a half months.

Active Comparator: Shock Wave Therapy with Traditional Physical Therapy

Participants will receive 12 sessions of extracorporeal shock wave therapy combined with traditional physical therapy, administered at a frequency of two sessions per week for a total duration of one and a half months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Shoulder pain (measured via numeric anlage scale)
Time Frame: Pre-post evaluation conducted across a treatment period of one and a half months (totaling 12 sessions at a frequency of two sessions per week).
Pre-post evaluation conducted across a treatment period of one and a half months (totaling 12 sessions at a frequency of two sessions per week).
Shoulder range of motion (measured via electronic goniometer)
Time Frame: Pre-post evaluation conducted across a treatment period of one and a half months (totaling 12 sessions at a frequency of two sessions per week).
Pre-post evaluation conducted across a treatment period of one and a half months (totaling 12 sessions at a frequency of two sessions per week).

Secondary Outcome Measures

Outcome Measure
Time Frame
Shoulder function (assessed by shoulder joint functional index)
Time Frame: Pre-post evaluation conducted across a treatment period of one and a half months (totaling 12 sessions at a frequency of two sessions per week).
Pre-post evaluation conducted across a treatment period of one and a half months (totaling 12 sessions at a frequency of two sessions per week).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Mohammed Abdelaziz Emam, master degree, Ass.lecturer, faculty of physical therapy, kafr elshiekh university
  • Principal Investigator: Yasmein Mohammed Mahmoud, PhD, faculty of physical therapy, kafr elshiekh university
  • Principal Investigator: Reda Fathi Elbosaty, bachelor student, faculty of physical therapy, kafr elshiekh university

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 10, 2026

Primary Completion (Estimated)

January 10, 2027

Study Completion (Estimated)

January 11, 2027

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • KFSIRB200-1210

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Data will be shared upon reasonable request from the principal investigator.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.